Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

@article{Tipping2004EfficacyOD,
  title={Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate},
  author={Alex J. Tipping and S S Baluch and David J Barnes and Darren R Veach and B. M. L. Clarkson and William G. Bornmann and François Xavier Mahon and John M. Goldman and Junia V. Melo},
  journal={Leukemia},
  year={2004},
  volume={18},
  pages={1352-1356}
}
Monotherapy of chronic myeloid leukemia (CML) with imatinib mesylate has been cast into shadow by the evolution of clinical resistance during therapy. Resistance to imatinib can arise by multiple mechanisms including amplification or mutation of Bcr-Abl, and continuity of imatinib therapy is probably a poor option for either of these patient groups. Recently, however, a structurally distinct new class of drugs, the pyrido[2,3-d]pyrimidines, has been described, and these compounds are predicted… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Chronic myeloid leukemia.

Hematology. American Society of Hematology. Education Program • 2003

Similar Papers

Loading similar papers…